Author

Jesus Aparicio

LINKING LOCATION SPECIFIC GENE EXPRESSION PATTERNS TO POTENTIAL VEDOLIZUMAB OUTCOMES IN CROHN’S DISEASE PATIENTS
LINKING LOCATION SPECIFIC GENE EXPRESSION PATTERNS TO POTENTIAL VEDOLIZUMAB OUTCOMES IN CROHN’S DISEASE PATIENTS

Jesus Aparicio  et al.

UNDERSTANDING THE IMPACT OF PREVIOUS TNF-ALPHA INHIBITORS ON VEDOLIZUMAB RESPONSE IN PATIENTS WITH ULCERATIVE COLITIS AND CROHN’S DISEASE USING SYSTEMATIC REVIEW AND GENE EXPRESSION DATA
UNDERSTANDING THE IMPACT OF PREVIOUS TNF-ALPHA INHIBITORS ON VEDOLIZUMAB RESPONSE IN PATIENTS WITH ULCERATIVE COLITIS AND CROHN’S DISEASE USING SYSTEMATIC REVIEW AND GENE EXPRESSION DATA

Jesus Aparicio  et al.

REAL WORLD EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB IN CROHN’S DISEASE WHEN USED AS A FIRST BIOLOGIC OR AFTER FAILURE OF ONE PREVIOUS ANTI-TNF (EVOLVE-IB STUDY)
REAL WORLD EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB IN CROHN’S DISEASE WHEN USED AS A FIRST BIOLOGIC OR AFTER FAILURE OF ONE PREVIOUS ANTI-TNF (EVOLVE-IB STUDY)

Jesus Aparicio  et al.

OBSERVATIONAL STUDY ON THE EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB IN AN ULCERATIVE COLITIS POPULATION COMPRISED BY BIO-NAÏVE PATIENTS AND PATIENTS WITH FAILURE OF ONE PREVIOUS ANTI-TNF (EVOLVE-IB STUDY)
OBSERVATIONAL STUDY ON THE EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB IN AN ULCERATIVE COLITIS POPULATION COMPRISED BY BIO-NAÏVE PATIENTS AND PATIENTS WITH FAILURE OF ONE PREVIOUS ANTI-TNF (EVOLVE-IB STUDY)

Jesus Aparicio  et al.

Item 1 - 4 / 4
1